Business Context and Reporting Period
This Form 8-K Current Report was filed by Predictive Oncology Inc. (not Axe Compute Inc.) on August 26, 2025. The filing discloses the entry into a Material Agreement and the unregistered sale of equity securities. The company is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol POAI.
Key Financial Metrics
The filing details a private placement transaction rather than periodic financial performance metrics. Key figures include:
- Shares Sold: 543,544 shares of common stock.
- Purchase Price: $0.76 per share.
- Gross Proceeds: Approximately $413,093 (before offering expenses).
- Use of Proceeds: Working capital and general corporate purposes.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes
The primary material change is the completion of a private placement offering on August 26, 2025. This transaction increases the company's share count and provides immediate capital. Additionally, the company has agreed to restrictions on issuing new common stock or equivalents through October 31, 2025, subject to exceptions.
Guidance, Outlook, and Risks
Management Commentary: The company intends to utilize net proceeds for working capital and general corporate purposes. The filing notes that the investor was granted a 100% participation right in future equity offerings through October 31, 2025.
Regulatory Obligations: The company is required to file a registration statement with the SEC for the resale of the shares within 90 days of the agreement date.
Risks and Contingencies: The filing states that representations and warranties were made solely for the benefit of the parties to the agreement and may be subject to limitations. The full text of the Purchase Agreement will be filed as an exhibit to the Form 10-Q for the quarter ended September 30, 2025.
Investor Verification Checklist
- Verify the discrepancy between the requested company name ("Axe Compute Inc.") and the actual registrant ("Predictive Oncology Inc.").
- Confirm the final net proceeds after deducting offering expenses, as only gross proceeds are listed.
- Review the upcoming Form 10-Q for the full text of the Purchase Agreement and specific restrictions on future issuances.
- Monitor the filing of the resale registration statement within the 90-day window.
- Assess the impact of the 100% participation right granted to the investor on future capital raising efforts.